NCT03170180View on ClinicalTrials.gov

Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

October 31, 2021

Study Completion Date

December 28, 2021

Conditions

Stomach Neoplasms

Interventions

DRUG

Sunitinib

sunitinib 37.5mg daily

DRUG

Gefitinib

Gefitinib 250mg daily

DRUG

Imatinib

Imatinib 400mg daily

Trial Locations (1)

Unknown

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Samsung Medical Center

OTHER

NCT03170180 - Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer | Biotech Hunter | Biotech Hunter